Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.17% is 109% below its 5-year average of -21.12%, near the low end of its 5-year range (-44.77%–4.43%).
16.94% below its 12-month average of -37.77%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.02%.
RETURN ON ASSETS (ROA)
-44.17%
RETURN ON ASSETS (ROA) AVG TTM
-37.77%
RETURN ON ASSETS (ROA) AVG 3Y
-27.61%
RETURN ON ASSETS (ROA) AVG 5Y
-21.12%
RETURN ON ASSETS (ROA) AVG 10Y
-23.98%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.94%
CURRENT VS 3Y AVG
-59.96%
CURRENT VS 5Y AVG
-109.15%
CURRENT VS 10Y AVG
-84.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 500 covered companies
CURRENT VS SECTOR MEDIAN
-64.20%
vs the sector median at left
Denali Therapeutics Inc.
Market Cap
$3.16B
Return on Assets (ROA)
-44.17%
TTM Avg
-37.77%
3Y Avg
-27.61%
5Y Avg
-21.12%
Market Cap
$3.15B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
Market Cap
$3.09B
Return on Assets (ROA)
-57.49%
TTM Avg
-99.67%
3Y Avg
-60.13%
5Y Avg
-103.92%
Market Cap
$3.25B
Return on Assets (ROA)
-11.64%
TTM Avg
-24.55%
3Y Avg
-30.16%
5Y Avg
-27.23%
Market Cap
$2.88B
Return on Assets (ROA)
-52.25%
TTM Avg
-41.76%
3Y Avg
-70.33%
5Y Avg
-55.50%
Market Cap
$3.44B
Return on Assets (ROA)
21.83%
TTM Avg
22.04%
3Y Avg
-0.21%
5Y Avg
-10.13%
Market Cap
$2.87B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$2.87B
Return on Assets (ROA)
1.56%
TTM Avg
-4.54%
3Y Avg
-5.50%
5Y Avg
-3.43%
Market Cap
$3.58B
Return on Assets (ROA)
-1.28%
TTM Avg
-8.27%
3Y Avg
-17.73%
5Y Avg
-16.90%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | $3.16B | -44.17% | -37.77% | -27.61% | -21.12% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 5.84% | -21.93% | -47.49% | -47.67% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -57.49% | -99.67% | -60.13% | -103.92% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | -11.64% | -24.55% | -30.16% | -27.23% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -52.25% | -41.76% | -70.33% | -55.50% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 21.83% | 22.04% | -0.21% | -10.13% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 10.36% | 11.11% | 1.40% | -7.68% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 1.56% | -4.54% | -5.50% | -3.43% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.58B | -1.28% | -8.27% | -17.73% | -16.90% |
| Celcuity Inc. (CELC)vs › | $3.59B | -27.35% | -41.78% | -34.97% | -41.24% |
ROA
-44.2%
ROE
-61.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -44.77% |
| 2024-12-31 | -30.77% |
| 2023-12-31 | -12.59% |
| 2022-12-31 | -22.32% |
| 2021-12-31 | -20.69% |
| 2020-12-31 | 4.43% |
| 2019-12-31 | -35.72% |
| 2018-12-31 | -5.47% |
| 2017-12-31 | -18.12% |
| 2016-12-31 | -31.97% |
| 2015-12-31 | -45.77% |
